Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.38 |
| ▸ | CA2 | P00918 | 7/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13764199 | 0.90 | CA1 (0.37) | CA1CA2POLBALDH1A1HSD17B10 | |
| SCHEMBL12141371 | 0.89 | CA1 (0.36) | CA1CA2POLBALDH1A1HSD17B10 | |
| SCHEMBL13764196 | 0.89 | CD40 (0.43) | CA1CA2POLBALDH1A1HSD17B10 | |
| SCHEMBL13764186 | 0.87 | RAB9A (0.38) | CA1CA2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL13764187 | 0.86 | HDAC2 (0.40) | CA1CA2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL13764192 | 0.86 | POLB (0.40) | CA1CA2POLBALDH1A1HSD17B10 | |
| SCHEMBL12141427 | 0.86 | ALDH1A1 (0.40) | CA1CA2ALDH1A1KDM4ENPSR1 | |
| SCHEMBL12141395 | 0.86 | HTT (0.36) | ALDH1A1HSD17B10SMN1; SMN2GAAKMT2A | |
| SCHEMBL12141386 | 0.86 | HDAC2 (0.41) | ALDH1A1KMT2A | |
| SCHEMBL13764197 | 0.85 | ALDH1A1 (0.39) | CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557176-B2 | Polyhydroxyalkanoic acid having vinyl, ester, carboxyl or sulfonic acid group and producing method therefor | CANON KABUSHIKI KAISHA (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20080064828-A1 | Polyhydroxyalkanoic Acid Having Vinyl, Ester, Carboxyl or Sulfonic Acid Group and Producing Method Therefor | CANON KABUSHIKI KAISHA (JP) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064828-A1 | Polyhydroxyalkanoic Acid Having Vinyl, Ester, Carboxyl or Sulfonic Acid Group and Producing Method Therefor | FAR1, ACSL4, ACAD11 | CA1 1473/4885CA2 1054/4885POLB 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.